MD Anderson Study Reveals Macrophage Dysfunction, Not Absence, Drives Aggressive Skin Cancer in Immunosuppressed Patients
核心洞察
Researchers at MD Anderson Cancer Center found that immunosuppressed patients with non-melanoma skin cancer (搜索) retain macrophages (搜索), but these cells lose their ability to communicate effectively with T cells.
The study analyzed tumors from 138 patients and revealed a five-year overall survival rate of 33% for immunosuppressed patients versus 68.8% for those with normal immune function.
Single-cell analysis showed reduced receptor diversity and impaired cancer-related signaling in macrophages (搜索) from immunosuppressed individuals, challenging the long-held belief that these patients simply lack key immune cells.
A landmark study from The University of Texas MD Anderson Cancer Center has upended a long-standing assumption about why immunosuppressed patients with non-melanoma skin cancer (搜索) fare so poorly: the critical immune cells are present, but they have lost the ability to communicate. The findings, published today in Cell, point toward entirely new treatment strategies for a patient population historically excluded from immunotherapy trials.
"For years, treating these patients has been very challenging, even in the era of immunotherapy. The prevailing thought has long been that these patients simply have fewer of these important immune cells, but that is not what we saw," said Moran Amit, M.D., Ph.D., assistant professor of Head and Neck Surgery at MD Anderson and co-lead of the study. "We learned that the quality of the immune cells and their interactions may be just as important as the number of cells present. This is an important finding because these patients need better treatment options."
A stark survival disparity
Non-melanoma skin cancer (搜索) is the most common cancer in the United States, and individuals with weakened immune systems — including organ transplant recipients and those with certain blood cancers — are disproportionately affected by aggressive forms of the disease. Their immunosuppressed status routinely excludes them from receiving immune checkpoint inhibitors (搜索), leaving them with no immunotherapy options.
The research team analyzed tumors from 138 patients with non-melanoma skin cancer (搜索). The survival data underscored the clinical urgency: patients with weakened immune systems had a five-year overall survival rate of just 33%, compared to 68.8% for patients with normal immune function. Disease-free survival was also significantly shorter in the immunosuppressed cohort.
Macrophages (搜索): present but silenced
Macrophages (搜索), a type of white blood cell, normally coordinate the body's immune response by helping T cells recognize and attack cancer. Using single-cell analysis, the researchers discovered that tumors from immunosuppressed patients contained many of the same immune-cell types found in immunocompetent patients. However, these macrophages were markedly less effective at sending cancer-related signals to other cells.
Critically, the macrophages (搜索) in immunosuppressed patients exhibited reduced receptor diversity, suggesting that their capacity to recognize cancer cells was more limited. Rather than an absence of immune cells, the problem appears to be a functional silencing of the innate immune compartment.
The study was co-led by Kunal Rai, Ph.D., associate professor of Genomic Medicine; Frederico Gleber-Netto, D.D.S., Ph.D., assistant professor of Head and Neck Surgery; Priyadharsini Nagarajan, M.D., Ph.D., associate professor of Anatomic Pathology; and Michael Migden, M.D., professor of Dermatology, alongside collaborators from Cleveland Clinic, Moffitt Cancer Center, and the University of Pennsylvania.
Shifting the therapeutic paradigm
The findings fundamentally reframe how researchers and clinicians might approach immunosuppressed cancer patients. Rather than attempting to boost T-cell activity — the mechanism of conventional checkpoint inhibitors — the study suggests that targeting macrophage functionality and restoring immune cell communication within the tumor microenvironment could be a more viable strategy.
"Now that we know the cells are there, it changes how we approach this problem," Amit said. "We are now investigating efforts to boost the cells or help them recover their lost functionality. That's a shift in how we approach this disease, but it could lead to promising new avenues of research for treatments."
The research highlights the importance of innate immunity in shaping antitumor responses and raises the possibility of developing therapies that either prevent the functional decline of macrophages (搜索) or reverse it, potentially opening immunotherapy doors for patients who have long been left without them.